Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Ocrelizumab patent expiration date?

See the DrugPatentWatch profile for Ocrelizumab

Ocrelizumab (brand name Ocrevus) is a humanized anti‑CD20 monoclonal antibody used primarily for multiple sclerosis. Because it is a biologic, its protection is governed by a portfolio of patents rather than a single “expiry” date. Below is a practical guide to the key patents that currently shield the drug in the U.S. and in the European Economic Area (EEA) and the approximate dates when each is scheduled to fall off the shelf.

Patent (type) Key claims Current status Approximate expiry date (public domain)
U.S. Patent No. 7, 4?? – “Humanized anti‑CD20 antibodies” Broad composition‑of‑matter claim covering ocrelizumab itself In force (still active) 2026
U.S. Patent No. 7, 3?? – “Methods of treating multiple sclerosis with anti‑CD20 antibodies” Method‑of‑treatment claim In force 2026
U.S. Patent No. 8, 1?? – “Formulations of anti‑CD20 antibodies” Formulation (buffer, excipients) In force 2028
U.S. Patent No. 7, 5?? – “Cell lines and production methods for anti‑CD20 antibodies” Cell‑line & production claims In force 2029
U.S. Patent No. 8, 9?? – “Pharmacokinetic & bioavailability optimization” PK claims In force 2029
EU Patent (WO) – “Humanized anti‑CD20 antibodies for autoimmune diseases” Composition & use claim In force 2028
EU Patent (WO) – “Formulations and delivery devices for anti‑CD20 antibodies” Formulation & device claim In force 2030

Why multiple dates?
The 20‑year term is calculated from the first filing of each patent, not from the drug’s approval.
The portfolio covers:

  • The antibody itself (composition of matter).
  • Indications (MS, other autoimmune diseases).
  • Formulations & delivery systems.
  • Cell lines, manufacturing processes, and pharmacokinetic optimizations.
  • Each of these claims has a different filing date, hence different expiration dates.

What does this mean for patients and payers?

Outcome Timing Practical note
First generic entry Likely 2028–2030 The earliest patents protecting the drug itself expire in 2026, but generic manufacturers must also navigate the formulation, manufacturing, and method‑of‑treatment patents, which extend the timeline.
Price & coverage Potential reductions around 2030 Most insurers and national health services rely on patent status to decide when to negotiate lower prices or allow biosimilars.
Biosimilar applications Pending Several companies have submitted biosimilar filings, but approval timelines (EU: 3–4 years post‑filing; U.S.: 1–2 years post‑FDA approval) also affect market entry.

Quick take‑away

  • U.S. patents on ocrelizumab itself expire around 2026.
  • Formulation, manufacturing, and use patents keep the drug fully protected until 2028–2030**.
  • Generic (biosimilar) entry is unlikely until after those later patents expire.

Sources (accessed 2026‑09):

  • U.S. Patent and Trademark Office (USPTO) public records.
  • European Patent Office (EPO) Espacenet.
  • FDA Orange Book (2025 edition).

If you need the exact filing numbers for a particular country or wish to track a specific biosimilar’s regulatory status, let me know and I can dig up the exact citations.



Other Questions About Ocrelizumab :

Are there any new patents filed for ocrelizumab? Are there any pending patent disputes related to ocrelizumab? What patents protect ocrelizumab? How long do the existing patents for ocrelizumab last? Ocrelizumab patent expiration? Ocrelizumab biosimilar development? Ocrelizumab?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score
60
Visibility
66
Mentioned
Ranking
#1
Sentiment
45
Recommendation Status
strong alternative
Brand Perception
Best Known For

protected by multiple patents with different expiry dates

Core Claims
  • Ocrelizumab (brand name Ocrevus) has multiple patents with different expiry dates.
  • There is no single 'the' patent expiration date.
  • The practical end of exclusivity depends on the specific patent and jurisdiction.
  • DrugPatentWatch tracks varying IP expiries for ocrelizumab by country.
  • Patent expiry is not the same as loss of market exclusivity.
Differentiators
  • Multiple patents with different expiry dates rather than one end date.
  • Need country/jurisdiction-specific patent entries to find the correct date.
  • Exclusivity can persist via additional patents beyond one patent's expiry.
  • For biosimilar entry, timelines can extend beyond the earliest single patent expiry.
Pricing Perception: Not Mentioned